

# 東アジアにおける婦人科がん領域の臨床試験/治験ネットワーク EAGOT (East Asian Gynecologic Oncology Trial Group) の構築

織田 克利<sup>\*1, #</sup>, 岡本 愛光<sup>\*2</sup>, 榎本 隆之<sup>\*3</sup>

(受付: 令和4年8月4日, 受理: 令和4年12月6日)

## Establishment of EAGOT (East Asian Gynecologic Oncology Trial Group), a Clinical Research Network for Gynecologic Malignancies in East Asia

Katsutoshi ODA<sup>\*1, #</sup>, Aikou OKAMOTO<sup>\*2</sup> and Takayuki ENOMOTO<sup>\*3</sup>

### Summary

JGOG (Japan Gynecologic Oncology Group) is one of the most comprehensive research networks dealing with gynecologic malignancies, with broad experience of clinical trials (both domestic and international). In 2021, JGOG founded EAGOT (East Asian Gynecologic Oncology Trial Group) with 3 other Asian clinical trial groups; KGOG (Korean Gynecologic Oncology Group) from South Korea, CGCS (Chinese Gynecologic Cancer Society) from China, and TGOG (Taiwanese Gynecologic Oncology Group) from Taiwan. An ARO network, to which the principal investigators in each clinical trial belong, has been constructed by domestic institutions. Results: Various types of investigator-initiated phase 2/3 trials involving JGOG in collaboration with KGOG are currently under preparation in EAGOT with universal protocols, an ICH-GCP based ARO data center, and CDISC standards. Our randomized phase 3 trials aim to establish standardized treatment guidelines, including adjuvant chemotherapy versus concurrent chemoradiotherapy, for postoperative cervical cancer, as well as adjuvant chemotherapy versus observation in stage I epithelial ovarian cancer after comprehensive staging surgery. Investigator-initiated phase 2 clinical trials focus on taking forward unapproved drugs such as PARP inhibitors and immune checkpoint inhibitors for future approval. Development of international registry systems and translational research with virtual slides, AI deep-learning studies and multi-omics analyses are also in progress. Cooperation of JGOG/EAGOT with the ARO network can provide a core global research network for big-data clinical trials in Asia. We believe this approach will contribute to expansion of various types of nationwide “disease-specific” consortia into global clinical trial networks.

### Key words

Medical innovation network, Gynecologic oncology consortium, Investigator-initiated clinical trial, Real world data, Multi-omics analysis